Pharmaceuticals News and Research

RSS

Study shows how chronic psychological stress leads to sickle cell crises

A new study shows how chronic psychological stress leads to painful vessel-clogging episodes--the most common complication of sickle-cell disease (SCD) and a frequent cause of hospitalizations.

30 Jul 2020

KHN’s ‘What the Health?’: Republicans in COVID disarray

President Donald Trump's pivot to a more serious view of the coronavirus pandemic didn't last long. This week, he was again touting hydroxychloroquine, an antimalarial drug that has not been shown to work against the virus.

30 Jul 2020

Botox injections can reduce depression, shows study

Botox, a medication derived from a bacterial toxin, is commonly injected to ease wrinkles, migraines, muscle spasms, excessive sweating and incontinence.

30 Jul 2020

Compounds demonstrate promising activity against tuberculosis

Compounds tested for their potential as antibiotics have demonstrated promising activity against one of the deadliest infectious diseases - tuberculosis (TB).

30 Jul 2020

Pimavanserin reduced psychotic symptoms in people with dementia in phase 3 study

A large-scale trial has found a treatment with pimavanserin substantially reduced psychotic symptoms and reduced risk of relapse of those symptoms compared to placebo in people with dementia, a condition for which no treatments are currently licensed.

29 Jul 2020

Public health experts fear a hasty FDA signoff on vaccine

The vaccine trial that Vice President Mike Pence kicked off in Miami on Monday gives the United States the tiniest chance of being ready to vaccinate millions of Americans just before Election Day.

29 Jul 2020

DSI to conduct digital partnering meetings during BIO International Convention

Design Space InPharmatics, a Regulatory Drug Development Consulting Firm provides Chemistry, Manufacturing and Controls regulatory, technical, and project management consulting services to healthcare product companies that manufacture and/or market pharmaceuticals, biopharmaceuticals, and and gene therapy products.

From DSI, a PLG Company 29 Jul 2020

COVID-19 DSI operation update

We are truly living in a new age of communication, between video conferences and virtual work meetings, to live recorded strategy and operational discussions, we are all doing our best to stay in touch and stay distant at the same time.

From DSI, a PLG Company 29 Jul 2020

Research may lead to improved treatments for mental health

The National Institutes of Health awarded Penn State researchers a $1.85 million grant to develop a new way to test if dysfunctions in certain areas of the brain lead to mental health complications and brain disorders. If proven, the research would lead to better mental health treatments.

25 Jul 2020

UCC Innovation launches new spinout company SeqBiome

UCC Innovation today announced the launch of SeqBiome a spinout from APC Microbiome Ireland, SFI Research Centre, University College Cork and Teagasc (the Irish Agriculture and Food Development Authority).

24 Jul 2020

New model may explain why certain cancer cells are resistant to therapy

Cancer's knack for developing resistance to chemotherapy has long been a major obstacle to achieving lasting remissions or cures.

24 Jul 2020

Combining two immunotherapies into a single treatment found to be more effective

Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patient's immune system to attack cancer. But immunotherapies don't work in all patients, and researchers have been searching for ways to increase their effectiveness.

23 Jul 2020

Eikonoklastes Therapeutics announces closing of oversubscribed seed financing

Eikonoklastes Therapeutics, a preclinical stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies for triple-negative breast cancer (TNBC) and several other diseases with unmet clinical need, today announced closing of an oversubscribed seed financing.

23 Jul 2020

Study finds viable drug target for triple negative breast cancer

One member of a larger family of oxygen sensing enzymes could offer a viable target for triple negative breast cancer (TNBC), UTSW researchers report in a new study.

23 Jul 2020

Vesigen Therapeutics to develop and commercialize novel drug-delivery technologies

Harvard University's Office of Technology Development (OTD) and the Harvard T.H. Chan School of Public Health today announced the launch of Vesigen Therapeutics, a startup company that aims to overcome the challenge of delivering next-generation therapeutics, such as gene-editing complexes, RNA molecules, and other large proteins, to intracellular targets in specific tissues of interest.

23 Jul 2020

Arcturus and Duke-NUS announce approval of clinical trials for COVID-19 vaccine candidate

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, and Duke-NUS Medical School, Singapore's flagship research-intensive graduate entry medical school, today announced that the Clinical Trial Application for COVID-19 vaccine candidate LUNAR-COV19 has been approved to proceed by the Singapore Health Sciences Authority.

22 Jul 2020

Scientific evidence shows GLDH is a safe biomarker for drug-induced liver injury

Critical Path Institute (C-Path) announced today that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) from the U.S. Food and Drug Administration (FDA) issued a positive response to the Qualification Plan (QP) for glutamate dehydrogenase (GLDH) as a safety biomarker for drug-induced liver injury (DILI), developed by C-Path's Predictive Safety Testing Consortium (PSTC) and Duchenne Regulatory Science Consortium (D-RSC).

22 Jul 2020